The Human Phenotype Ontology (HPO) provides the following list of features that have been reported in people with this condition. Much of the information in the HPO comes from Orphanet, a European rare disease database. If available, the list includes a rough estimate of how common a feature is (its frequency). Frequencies are based on a specific study and may not be representative of all studies. You can use the MedlinePlus Medical Dictionary for definitions of the terms below.
|Signs and Symptoms||Approximate number of patients (when available)|
|Abnormality of the stomach||90%|
|Lack of skin elasticity||90%|
|Nausea and vomiting||90%|
|Restrictive ventilatory defect||90%|
|Abnormal pattern of respiration||50%|
|Abnormal tendon morphology||50%|
|Abnormality of the pericardium||50%|
|Coronary artery disease||50%|
|Cranial nerve paralysis||50%|
|Decreased nerve conduction velocity||50%|
|Feeding difficulties in infancy||50%|
|Hypopigmented skin patches||50%|
|Recurrent urinary tract infections||50%|
|Telangiectasia of the skin||50%|
|Congestive heart failure||7.5%|
|Neoplasm of the lung||7.5%|
|Skeletal muscle atrophy||7.5%|
The following medications may be used to treat scleroderma:
More detailed information regarding the treatment of scleroderma can be accessed through MedScape.
Research helps us better understand diseases and can lead to advances in diagnosis and treatment. This section provides resources to help you learn about medical research and ways to get involved.
Nonprofit support and advocacy groups bring together patients, families, medical professionals, and researchers. These groups often raise awareness, provide support, and develop patient-centered information. Many are the driving force behind research for better treatments and possible cures. They can direct people to research, resources, and services. Many groups also have experts who serve as medical advisors. Visit their website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.
These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.
International Workshop on Scleroderma Research
Saturday, August 1, 2015 -
Wednesday, August 5, 2015
Location: Cambridge, United Kingdom
Description: The goals of this workshop are to provide for scientific interchange, promote collaboration and involve outstanding investigators in other fields. These scientific interactions with investigators traditionally outside of scleroderma (SSc) research are particularly important because SSc affects many different organ systems
Contact: James Witter, (301) 594-5032,email@example.com
Co-funding Institute(s): National Institute of Arthritis and Musculoskeletal and Skin Diseases, Office of Rare Diseases Research
Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know. Submit a new question
Is mixed connective tissue disorder more common in any ethnic population? See answer
How might scleroderma be treated? See answer